Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the 2022 Omnibus Equity Incentive Plan of ZyVersa Therapeutics, Inc. of our report dated March 31, 2023 (except for the effects of the reverse stock split discussed in Note 14, as to which the date is December 4, 2023), with respect to the consolidated financial statements of ZyVersa Therapeutics, Inc. for the year ended December 31, 2022 included in the Form S-1 (Registration No. 333-257320) filed with the Securities and Exchange Commission.
/s/ Ernst & Young LLP
Orlando, Florida
February 14, 2024
